The role of osteoprotegerin in breast and prostate cancer

The role of osteoprotegerin in breast and prostate cancer

Detaylı Bibliyografya
Asıl Yazarlar:	Holen, I, Wells, J, Croucher, P, Evans, C, Lippitt, J, Coleman, R, Jagdev, S, Hamdy, F, Eaton, C
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	2002

Benzer Materyaller

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
Yazar:: Eaton, C, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
Yazar:: Eaton, C, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

OPG is a survival factor for breast- and prostate cancer cells in vitro
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
Yazar:: Shipman, C, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
Yazar:: Waterman, E, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Role of osteoprotegerin (OPG) in cancer.
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
Yazar:: Shipman, C, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
Yazar:: Nyambo, R, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Osteoprotegerin and the development of myeloma bone disease
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
Yazar:: Holen Ingunn, ve diğerleri
Baskı/Yayın Bilgisi: (2009-07-01)

Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis
Yazar:: Nyambo, R, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
Yazar:: Shipman, C, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Yazar:: Jagdev, S, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study.
Yazar:: Glen, A, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Bone marrow stromal cell-derived insulin-like growth factor (IGF) II enhances growth and survival of prostate cancer cells and potentiates androgen action
Yazar:: Cross, N, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Human bone marrow stromal cell derived IGF signaling enhances PSA production as well as proliferation/survival of androgen sensitive prostate cancer cells in vitro
Yazar:: Papageorgiou, M, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

OSTEOPROTEGERIN AS A PREDICTIVE MARKER OF THE COURSE OF BREAST CANCER
Yazar:: S. I. Zabroda, ve diğerleri
Baskı/Yayın Bilgisi: (2015-04-01)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells
Yazar:: Cross, N, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.
Yazar:: Cross, N, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Imaging the effects of castration on bone turnover and hormone-independent prostate cancer colonization of bone.
Yazar:: Cross, N, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Prostate cancer proteomics: The urgent need for clinically validated biomarkers
Yazar:: Evans, C, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Analysis of the functional role of ADAMTS enzymes in prostate cancer
Yazar:: Molokwu, C, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
Yazar:: De Leenheer, E, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer
Yazar:: Horikawa Yohei, ve diğerleri
Baskı/Yayın Bilgisi: (2008-08-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
Yazar:: Shipman, C, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Osteoprotegerin in Cardiometabolic Disorders
Yazar:: C. Pérez de Ciriza, ve diğerleri
Baskı/Yayın Bilgisi: (2015-01-01)

The roles of osteoprotegerin in cancer, far beyond a bone player
Yazar:: Yufei Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Yazar:: Shipman, C, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Loss of intercellular expression of beta-dystroglycan is a common event in prostate cancer and is significantly associated with loss of differentiation
Yazar:: Cross, S, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.
Yazar:: Itonaga, I, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Expression pattern of the ADAMTS (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) proteinases in human prostate cancer celllines
Yazar:: Chandrasekharan, S, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
Yazar:: Vanderkerken, K, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin
Yazar:: Peggy Benad-Mehner, ve diğerleri
Baskı/Yayın Bilgisi: (2014-03-01)

Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation
Yazar:: Sarah Sohyun Park, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)